NCT01923337View on ClinicalTrials.gov

Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

October 17, 2016

Study Completion Date

October 17, 2016

Conditions
Mucinous Adenocarcinoma of the ColonMucinous Adenocarcinoma of the RectumRecurrent Colon CancerRecurrent Rectal CancerSignet Ring Adenocarcinoma of the ColonSignet Ring Adenocarcinoma of the RectumStage IIIA Colon CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

irinotecan hydrochloride

Given IV

DRUG

alisertib

Given PO

Trial Locations (1)

95817

UC Davis Comprehensive Cancer Center, Sacramento

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

University of California, Davis

OTHER

NCT01923337 - Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer | Biotech Hunter | Biotech Hunter